Veterans with Advanced Cancer to Have Better Access to Foundation Medicine’s Comprehensive Genomic Profiling Tests to Help Inform Personalized Treatment Plans   CAMBRIDGE, Mass. -- February 5, 2019 --  Foundation Medicine, Inc. today announced a nationwide contract with the U.S.

Proven biopharma executive leader, Cindy Perettie, named as chief executive officer to succeed Troy Cox   CAMBRIDGE, Mass. – January 7, 2019 – Foundation Medicine, Inc. today announced the appointment of Cindy Perettie as chief executive officer, effective February 4, 2019. Ms.

Breakthrough Approval Enables Patient Access to Comprehensive Genomic Profiling and Advances Oncology Therapy Development in Japan CAMBRIDGE, Mass.-- December 27, 2018 -- Foundation Medicine, Inc. today announced that Japan’s regulatory agency, the Ministry of Health, Labour and Welfare (MHLW) has

Novartis to Leverage Foundation Medicine’s Molecular Information Solutions to Develop Companion Diagnostics for Cancer Therapies CAMBRIDGE, Mass.-- October 17, 2018 -- Foundation Medicine, Inc. today announced a strategic collaboration with Novartis allowing the development of companion diagnostic

– FoundationOne Liquid analyzes 70 genes known to drive cancer growth and reports microsatellite instability high (MSI-high) status to inform the use of precision oncology treatments, including immunotherapies, with a simple blood draw – CAMBRIDGE, Mass.

-- New publication details Foundation Medicine’s assay’s ability to measure bTMB and to identify patients who may benefit from anti-PD-L1 therapy -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 6, 2018-- Foundation Medicine , today announced the publication of the results of a large study demonstrating

Basel, 31 July 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Roche’s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all

CAMBRIDGE, Mass. & REDWOOD CITY, Calif. --(BUSINESS WIRE)--Jul. 18, 2018-- Foundation Medicine, Inc. (NASDAQ:FMI) and Guardant Health, Inc . announced an agreement to settle a patent infringement lawsuit brought by Foundation Medicine against Guardant concerning U.S. Patent No. 9,340,830.

Basel, 2 July 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a price of US$ 137.00 per share. The tender offer is being made pursuant to the

Together, the companies will leverage expertise  in genomics and molecular information to enhance the development of personalised medicines and care for patients with cancer Merger focuses on driving ubiquity of Foundation Medicine's high quality comprehensive genomic profiling (CGP) testing and